Synonym
CI 922; CI-922; CI922; UNII-5VC7KY707F.
IUPAC/Chemical Name
3,7-dimethoxy-4-phenyl-N-(1H-tetrazol-5-yl)-4H-furo[3,2-b]indole-2-carboxamide (S)-2-amino-5-guanidinopentanoate
InChi Key
OLFPNWJCEUTPNJ-VWMHFEHESA-N
InChi Code
InChI=1S/C20H16N6O4.C6H14N4O2/c1-28-12-8-9-14-13(10-12)16-15(26(14)11-6-4-3-5-7-11)17(29-2)18(30-16)19(27)21-20-22-24-25-23-20;7-4(5(11)12)2-1-3-10-6(8)9/h3-10H,1-2H3,(H2,21,22,23,24,25,27);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t;4-/m.0/s1
SMILES Code
n1(c2ccccc2)c2c(c(oc2c2cc(OC)ccc12)C(=O)Nc1nnn[nH]1)OC.C([C@@H](N)CCCNC(=N)N)(=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
578.58
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Werns SW, Eller BT, Shea MJ, Simpson PJ, Dysko RC, Abrams GD, Lucchesi BR. Protection of reperfused ischemic canine myocardium by CI-922, a new inhibitor of leukocyte activation. J Cardiovasc Pharmacol. 1988;12(5):608-14. PubMed PMID: 2468062.
2: Wright CD, Hoffman MD, Thueson DO, Conroy MC. Inhibition of human neutrophil activation by the allergic mediator release inhibitor, CI-922: mechanism of inhibitory activity. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1110-7. PubMed PMID: 2825675.
3: Wright CD, Hoffman MD, Thueson DO, Conroy MC. Inhibition of human neutrophil activation by the allergic mediator release inhibitor, CI-922: differential inhibition of responses to a variety of stimuli. J Leukoc Biol. 1987 Jul;42(1):30-5. PubMed PMID: 2439626.
4: Adolphson RL, Finkel MP, Robichaud LJ. CI-922--a novel, potent antiallergic compound--II. Activity in animal models of allergy. Int J Immunopharmacol. 1987;9(1):51-60. PubMed PMID: 2438239.
5: Robichaud LJ, Stewart SF, Adolphson RL. CI-922--a novel, potent antiallergic compound--I. Inhibition of mediator release in vitro. Int J Immunopharmacol. 1987;9(1):41-9. PubMed PMID: 2438238.
6: Boctor AM, Pugsley TA. Effect of CI-922, a potential new antiallergy agent, on arachidonic acid metabolism in vitro. Inflammation. 1986 Dec;10(4):435-41. PubMed PMID: 2432012.
7: Eiseman IA, Reynolds DL, Johnson EL, Daftsios AC, Pachla LA. A validated liquid chromatographic method for the antiallergy agent CI-922 in dog and rat plasma. J Pharm Biomed Anal. 1986;4(4):491-6. PubMed PMID: 16867585.
